MEDP has been the subject of several other research reports. Zacks Investment Research lowered W. R. Grace & Co from a buy rating to a hold rating in a research report on Wednesday, May 1st. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Wolfe Research initiated coverage on Iqvia in a research report on Tuesday, April 2nd. They issued a market perform rating for the company. Robert W. Baird lifted their price target on Shopify from $208.00 to $269.00 and gave the stock an outperform rating in a research report on Tuesday, April 30th. Finally, TheStreet lowered Zumiez from a b rating to a c+ rating in a research report on Thursday, June 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $61.25.
Shares of MEDP stock opened at $62.56 on Monday. Medpace has a 12-month low of $43.78 and a 12-month high of $71.66. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $59.36. The company has a market capitalization of $2.24 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.96 and a beta of 1.56.
Several large investors have recently made changes to their positions in MEDP. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in shares of Medpace during the fourth quarter valued at approximately $87,000. Marshall Wace LLP purchased a new position in shares of Medpace during the first quarter valued at approximately $99,000. NumerixS Investment Technologies Inc purchased a new position in shares of Medpace during the fourth quarter valued at approximately $119,000. LS Investment Advisors LLC boosted its position in shares of Medpace by 215.5% during the first quarter. LS Investment Advisors LLC now owns 2,745 shares of the company’s stock valued at $162,000 after buying an additional 1,875 shares during the period. Finally, South Dakota Investment Council purchased a new position in shares of Medpace during the first quarter valued at approximately $189,000. Institutional investors and hedge funds own 76.70% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.